As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies

Upstream regulators of ion channel expression or function are an emerging frontier for novel pain targets

Danish pharma eyeing growth beyond loss of exclusivity for Rexulti, aiming for broad label in rare epilepsies

Plus: Intra-Cellular’s Caplyta scores a win in major depressive disorder; and readouts for Marinus, Ultragenyx weigh on shares

Plus: A comeback for Regulus? And updates from Acadia, MoonLake, Ventyx, Acelyrin, Sanofi and more

With Karuna’s PDUFA date and several readouts on the way, 2024 is still looking like an important year for progress in treating the disease

The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff

A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them